BOQI International Medical Announces First Quarter 2021 Financial Results
NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) -- BOQI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), a leading healthcare products and services provider in China, today announced its financial results for the first quarter ended March 31, 2021.
First Quarter 2021 Financial Highlights
|●||Revenues grew by $1.75 million, or by 423%, to $2.17 million for the first quarter of 2021 from $0.41 million in the same period of 2020.|
|●||Gross profit increased by $0.51 million, or by 620%, to $0.59 million for the first quarter 2021 from $0.08 million in the same period of 2020.|
|●||Gross margin increased to 27.32% for the first quarter 2021 from 19.84% in the same period of 2020.|
|For three months ended March 31|
|Differences due to rounding||2021||2020||% change|
|Revenues||$||2.17 million||$||0.41 million||423||%|
|Gross profit||$||0.59 million||$||0.08 million||620||%|
|Net loss from continuing operations||$||3,290,627||$||1,347,234||144||%|
|Net loss attributable to BOQI International Medical Inc.||$||3,333,242||$||2,194,875||52||%|
Mr. Tiewei Song, Chief Executive Officer and President of the Company, commented: “We are pleased to see both of our revenues and gross margins continued to be boosted by our expanded business operations and enhanced efficiency during the first quarter of 2021. These improvements support our strategy to build a comprehensive healthcare ecosystem in China with a focus on a high-end gynecology-focused hospital chain through both organic growth and bolt-on acquisition opportunities. We intend to maintain this momentum in order to achieve sustainable profitability and create value for our shareholders.”
Revenues for the three months ended March 31, 2021 and 2020 were $2.17 million and $0.41 million, respectively. Compared with the same period in 2020, revenue in the 2021 period increased by $1.75 million, or 423%, mainly due to the increase in sales of wholesale pharmaceuticals of $1.10 million and medical services of $0.70 million.
Revenues from the retail pharmacy segment for the three months ended March 31, 2021 was $0.12 million, generated from 5 retail pharmacy stores in Chongqing.
Revenues from wholesale medical devices segment for the three months ended March 31, 2021 and 2020 were $0.06 million and $0.25 million, respectively. The decrease is mainly due to low demand for medical devices during the first quarter, which is typical because of the long break during the Chinese New Year.
Cost of revenues
Cost of revenues for the three months ended March 31, 2021 and 2020 was $1.58 million and $0.33 million, respectively. The Company recorded an obsolescence loss of $0.03 million with respect to inventories, which was included in the cost of revenues for the three months ended March 31, 2021 compared with an obsolescence loss of $0.30 million for the same period in 2020. The decrease of inventory provision is due to the obsolescence of inventory held for sale by the Boqi pharmacies in Dalian, whose stores suffered from the lockdown policy in effect due to the COVID-19 pandemic.
Gross profit for the three months ended March 31, 2021 and 2020 was $0.59 million and $0.08 million, respectively. For the three months ended March 31, 2021 and 2020, we had a gross margin of 27.32% and 19.85%, respectively. For the three months ended March 31, 2021 and 2020, the gross profit margin of our: (i) retail pharmacy segment were 17.17% in 2021; (ii) wholesale medical devices segment were 52.73% and 19.73%, respectively; (iii) wholesale pharmaceuticals segments were 36.21% and 19.99%, respectively; and (iv) medical services segment was 9.32% for the three months ended March 31, 2021.
Operating expenses from continuing operations were $3.83 million for the three months ended March 31, 2021 as compared to $1.41 million for the same period in 2020, an increase of $2.43 million or 173%. The increase is primarily attributable to the inclusion of the operating expenses of the medical services segment of appropriately $0.32 million and the Chongqing Guanzan Technology Co., Ltd. (“Guanzan Group”) of approximately $0.51 million, which we acquired in March 2020, and the amortization of the discount relating to the convertible notes issued in 2021 of $1.61 million, and general operating expenses which primarily include legal expenses of $0.28 million and audit fee of $0.15 million and other compliance expense.
For the three months ended March 31, 2021 and 2020, we reported other expenses of $0.03 million and $0.02 million, respectively. Other expenses mainly consisted of interest expense relating to the bank loans of the Guanzan Group, Chongqing Guoyitang Hospital Co., Ltd. (“Guoyitang”) and Chaohu Zhongshan Minimally Invasive Hospital (“Zhongshan”).
The Company completed the acquisitions of Guoyitang and Zhongshan in February, 2021.
Net loss from continuing operation
Net loss from continuing operations was $3.29 million and $1.35 million for the three months ended March 31, 2021 and 2020, respectively. The increase was primarily due to the increase in operating expenses and the other expenses described above.
Net loss attributable to BOQI International Medical Inc.
As a result of the foregoing our net loss attributable to BOQI International Medical Inc. increased by $1.14 million to $3.33 million for the three months ended March 31, 2021 from $2.19 million for the three months ended March 31, 2020.
Cash and working capital
As of March 31, 2021, we had cash of $2.84 million and negative working capital of $0.18 million as compared to cash of $0.14 million and working capital of $9.62 million as of December 31, 2020.
About BOQI International Medical Inc.
BOQI International Medical Inc. was founded in 2006. In February 2019, the Board of Directors of the Company determined to focus on the healthcare industry. The Company is now exclusively a healthcare products and provider, offering a broad range of healthcare products and related services and operates two private hospitals. For more information, please visit www.usbimi.com.
Safe Harbor Statement
Certain matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties including, but not limited to, the Company’s ability to achieve profitable operations, its ability to continue to operate as a going concern, its ability to continue to meet NASDAQ continued listing requirements, the effects of the spread of the Coronavirus (COVID-19), the demand for the Company’s products and services in the People’s Republic of China, general economic conditions and other risk factors detailed in the Company’s annual report and other filings with the United States Securities and Exchange Commission.
Investor Relations Contact:
EverGreen Consulting Inc.
Phone: +1 571-464-9470 (from U.S.)
+86 13811768559 (from China)
BOQI INTERNATIONAL MEDICAL, INC. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
|March 31||December 31|
|Accounts receivable, net||7,169,691||6,686,552|
|Advances to suppliers||3,093,935||2,693,325|
|Amount due from related parties||41,012||-|
|Prepayments and other receivables||4,941,351||14,880,526|
|Operating lease-right of use assets||46,521||53,425|
|Total current assets||21,697,069||25,184,488|
|Deferred tax assets||181,451||193,211|
|Property, plant and equipment, net||1,769,927||910,208|
|Operating lease-right of use assets||1,572,515||-|
|Total non-current assets||28,049,456||8,017,651|
|LIABILITIES AND EQUITY|
|Long-term loans due within one year||496,974||34,201|
|Convertible promissory notes, net||5,132,530||3,328,447|
|Accounts payable, trade||10,183,541||5,852,050|
|Advances from customers||529,279||194,086|
|Amount due to related parties||791,581||226,514|
|Other payables and accrued liabilities||4,849,557||4,228,976|
|Total current liabilities||23,452,999||15,565,214|
|Lease liability-non current||1,396,148||22,457|
|Long-term loans - non-current||425,592||720,997|
|Total non-current liabilities||1,821,740||743,454|
|Common stock, $0.001 par value; 50,000,000 shares authorized; 20,131,488 and 13,254,587 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively||20,131||13,254|
|Additional paid-in capital||37,362,809||26,344,920|
|Accumulated other comprehensive income||853,795||1,003,392|
|Total BOQI International Medical Inc.’s equity||24,252,377||16,710,450|
|Total liabilities and equity||$||49,746,525||$||33,202,139|
BOQI INTERNATIONAL MEDICAL, INC. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN/LOSS
|For three months ended|
|COST OF REVENUES||1,575,743||332,299|
|Sales and marketing||452,636||41,070|
|General and administrative||3,380,014||1,364,952|
|Total operating expenses||3,832,650||1,406,022|
|LOSS FROM OPERATIONS||(3,240,389||)||(1,323,737||)|
|OTHER INCOME (EXPENSE)|
|Other (income)/ expense||(12,865||)||545|
|Total other income (expense), net||(31,490||)||(22,229||)|
|LOSS BEFORE INCOME TAXES||(3,271,879||)||(1,345,966||)|
|PROVISION FOR INCOME TAXES||18,748||1,268|
|NET LOSS FROM CONTINUING OPERATIONS||(3,290,627||)||(1,347,234||)|
|Income/(loss) from operations of discontinued operations||-||(854,957||)|
|Less: net income (loss) attributable to non-controlling interest||42,615||(7,316||)|
|NET LOSS ATTRIBUTABLE TO BOQI INTERATIONAL MEDICAL INC.||$||(3,333,242||)||$||(2,194,875||)|
|OTHER COMPREHENSIVE LOSS|
|Foreign currency translation adjustment||(149,597||)||(120,201||)|
|TOTAL COMPREHENSIVE LOSS||(3,440,224||)||(2,322,392||)|
|Less: comprehensive loss attributable to non-controlling interests||(10,886||)||(4,935||)|
|COMPREHENSIVE LOSS ATTRIBUTABLE TO BOQI INTERNATIONAL MEDICAL INC.||$||(3,429,338||)||$||(2,317,457||)|
|WEIGHTED AVERAGE NUMBER OF COMMON SHARES|
|Basic and diluted||16,693,038||9,271,641|
|INCOME (LOSS) PER SHARE|
|Continuing operation-Basic and diluted||$||(0.20||)||$||(0.15||)|
|Discontinued operation-Basic and diluted||$||-||$||(0.09||)|
|Basic and diluted||$||(0.20||)||$||(0.24||)|